(firstQuint)Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody.

 Subjects with chronic hives that do not respond to antihistamine treatment and have hives of unknown cause will be eligible.

 Subjects who meet the inclusion/exclusion criteria after the run-in phase will receive 3 doses of study medication.

 The study also involved blood draws and a punch biopsy of a hive.

 Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody@highlight

Study to determine the efficacy of benralizumab when compared to placebo in patients with chronic hives that do not respond to antihistamine treatment